Published in Clin Infect Dis on March 12, 2012
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology (2014) 2.17
Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis (2013) 1.65
The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS One (2015) 1.51
The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med (2014) 1.33
Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One (2013) 1.14
Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis (2012) 1.02
Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open (2013) 0.95
Hepatitis C screening: getting it right. Hepatology (2012) 0.94
Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations. BMJ Open (2016) 0.93
Chronic hepatitis C and liver fibrosis. World J Gastroenterol (2014) 0.92
It is time to change the paradigm for hepatitis C virus testing. Clin Infect Dis (2012) 0.90
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS (2014) 0.87
Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. PLoS One (2017) 0.85
Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review. BMC Public Health (2014) 0.84
Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One (2014) 0.83
Ending hepatitis C in the United States: the role of screening. Hepat Med (2014) 0.81
Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010. Am J Public Health (2013) 0.81
Cost-Effectiveness of HBV and HCV Screening Strategies - A Systematic Review of Existing Modelling Techniques. PLoS One (2015) 0.80
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80
Integrated screening for tuberculosis and HIV in tuberculosis contact investigations: lessons learned in North Carolina. Public Health Rep (2014) 0.79
Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: a pilot project undertaken at the Vancouver General Hospital. Can J Gastroenterol Hepatol (2014) 0.79
Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology (2015) 0.79
Hepatitis C virus in Mexican Americans: a population-based study reveals relatively high prevalence and negative association with diabetes. Epidemiol Infect (2015) 0.77
Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature. Risk Manag Healthc Policy (2015) 0.76
Hepatitis C - Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial. Trials (2016) 0.76
Screening for hepatitis C virus infection. Gastroenterol Hepatol (N Y) (2012) 0.75
Screening for hepatitis C in average and high-risk populations of Qatar using rapid point-of-care testing. United European Gastroenterol J (2015) 0.75
Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway. BMC Infect Dis (2017) 0.75
Impact of an Electronic Medical Record-Based System to Promote Human Immunodeficiency Virus/Hepatitis C Virus Screening in Public Hospital Primary Care Clinics. Open Forum Infect Dis (2017) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect (2011) 6.48
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med (2007) 5.83
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health (2001) 4.57
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
The burden of hepatitis C in the United States. Hepatology (2002) 3.16
Screening in brief intervention trials targeting excessive drinkers in general practice: systematic review and meta-analysis. BMJ (2003) 3.15
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol (2011) 3.11
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (2009) 3.10
Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA (1999) 2.97
Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS (2005) 2.91
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. J Hepatol (2011) 2.78
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA (1999) 2.78
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology (2010) 2.64
Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis (2010) 2.62
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol (2003) 2.42
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology (2006) 2.35
Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol (2008) 2.27
Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med (1997) 2.09
Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep (2007) 2.04
Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med (2005) 1.97
Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology (1999) 1.90
Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol (2002) 1.74
Integrating HIV screening into routine health care in resource-limited settings. Clin Infect Dis (2010) 1.70
Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med (2001) 1.65
Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology (2006) 1.55
Treating hepatitis C in the prison population is cost-saving. Hepatology (2008) 1.50
Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat (2000) 1.45
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology (2010) 1.38
Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment Pharmacol Ther (2010) 1.36
Health-state utilities in liver disease: a systematic review. Med Decis Making (2008) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens. J Viral Hepat (2006) 1.28
Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol (2009) 1.25
Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ (1997) 1.24
Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl (2002) 1.22
Effect of hepatitis C virus and its treatment on survival. Hepatology (2009) 1.20
Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology (1994) 1.14
Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol (2002) 1.11
Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer (2008) 1.11
Outcomes of a Hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol (2008) 1.10
Influence of hepatitis C status on alcohol consumption in opiate users in treatment. Addiction (2001) 1.10
Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis (2007) 1.09
Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl (2010) 1.08
Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol (2005) 1.08
An economic analysis of liver transplantation. Costs, insurance coverage, and reimbursement. Gastroenterol Clin North Am (1993) 1.08
Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol (2004) 1.02
The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess (2006) 1.00
Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Mod Pathol (2009) 0.99
The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection. Curr Gastroenterol Rep (2011) 0.94
Validity of FibroScan values for predicting hepatic fibrosis stage in patients with chronic HCV infection. J Dig Dis (2009) 0.93
The effects of hepatitis C recurrence on health-related quality of life in liver transplant recipients. Liver Int (2009) 0.93
HCV carriers with normal alanine aminotransferase levels: healthy persons or severely ill patients? Dealing with an everyday clinical problem. Eur J Intern Med (2009) 0.92
Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci (2011) 0.89
Prevalence of HCV and genotypes distribution in general population of Georgia. Georgian Med News (2008) 0.88
HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. Curr Pharm Des (2008) 0.87
Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat (2003) 0.87
The disposition of hepatitis C antibody-positive patients in an urban hospital. J Viral Hepat (2009) 0.85
Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clin Gastroenterol Hepatol (2005) 0.85
A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat (2007) 0.84
Specificity and sensitivity of 3rd generation EIA for detection of HCV antibodies among intravenous drug-users. New Microbiol (1993) 0.80
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. Pharmacotherapy (2007) 0.77
International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet (2007) 10.12
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med (2009) 9.38
Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med (2005) 7.61
AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol (2004) 6.97
Expenditures and health status among adults with back and neck problems. JAMA (2008) 6.11
A randomized trial of epidural glucocorticoid injections for spinal stenosis. N Engl J Med (2014) 5.01
The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med (2015) 4.75
Rapid magnetic resonance imaging vs radiographs for patients with low back pain: a randomized controlled trial. JAMA (2003) 4.52
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health (2007) 3.93
The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature (2005) 3.82
Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. Neuron (2003) 3.62
Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol (2004) 3.45
Targeted screening for primary HIV infection through pooled HIV-RNA testing in men who have sex with men. AIDS (2005) 3.40
Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm (2003) 3.34
Protein phosphorylation in signaling--50 years and counting. Trends Biochem Sci (2005) 3.19
The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology (2013) 2.98
Distinct enzyme combinations in AKAP signalling complexes permit functional diversity. Nat Cell Biol (2005) 2.84
Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. Nature (2006) 2.77
The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD (2005) 2.66
Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care (2008) 2.64
A comparison between audio computer-assisted self-interviews and clinician interviews for obtaining the sexual history. Sex Transm Dis (2004) 2.62
HIV serosorting as a harm reduction strategy: evidence from Seattle, Washington. AIDS (2009) 2.58
The coming epidemic of obesity in elderly Americans. J Am Geriatr Soc (2004) 2.55
Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med (2013) 2.54
Rising rates of syphilis in the era of syphilis elimination. Sex Transm Dis (2007) 2.41
Demographic, behavioral, and clinical characteristics of men with nongonococcal urethritis differ by etiology: a case-comparison study. Sex Transm Dis (2011) 2.41
Cardiovascular events associated with ipratropium bromide in COPD. Chest (2009) 2.36
Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care (2003) 2.33
Molecular basis of AKAP specificity for PKA regulatory subunits. Mol Cell (2006) 2.33
Regulation of GluR1 by the A-kinase anchoring protein 79 (AKAP79) signaling complex shares properties with long-term depression. J Neurosci (2002) 2.31
AKAP signaling complexes: getting to the heart of the matter. Trends Mol Med (2006) 2.29
Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. Med Care (2006) 2.28
Can we reliably benchmark health technology assessment organizations? Int J Technol Assess Health Care (2012) 2.27
AKAP mediated signal transduction. Annu Rev Pharmacol Toxicol (2002) 2.26
Prediction of HIV acquisition among men who have sex with men. Sex Transm Dis (2009) 2.26
HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis (2009) 2.23
Interaction with AKAP79 modifies the cellular pharmacology of PKC. Mol Cell (2010) 2.22
Suboptimal adherence to doxycycline and treatment outcomes among men with non-gonococcal urethritis: a prospective cohort study. Sex Transm Infect (2013) 2.16
Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm (2015) 2.15
AKAP150 signaling complex promotes suppression of the M-current by muscarinic agonists. Nat Neurosci (2003) 2.08
The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report. Value Health (2003) 2.07
Dynamic regulation of cAMP synthesis through anchored PKA-adenylyl cyclase V/VI complexes. Mol Cell (2006) 2.05
A-kinase anchoring proteins take shape. Curr Opin Cell Biol (2007) 2.03
Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol (2004) 2.03
Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy (2014) 2.02
Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA (2013) 2.00
An anchored PKA and PDE4 complex regulates subplasmalemmal cAMP dynamics. EMBO J (2006) 1.99
A WAVE-1 and WRP signaling complex regulates spine density, synaptic plasticity, and memory. J Neurosci (2007) 1.97
Loss of AKAP150 perturbs distinct neuronal processes in mice. Proc Natl Acad Sci U S A (2008) 1.96
Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction. J Pediatr (2002) 1.96
Retinal detachment and prophylaxis in type 1 Stickler syndrome. Ophthalmology (2007) 1.95
Rab32 is an A-kinase anchoring protein and participates in mitochondrial dynamics. J Cell Biol (2002) 1.93
A-kinase anchoring proteins: from protein complexes to physiology and disease. IUBMB Life (2009) 1.89
Persistence of racial differences in attitudes toward homosexuality in the United States. J Acquir Immune Defic Syndr (2010) 1.86
Loss of WAVE-1 causes sensorimotor retardation and reduced learning and memory in mice. Proc Natl Acad Sci U S A (2003) 1.86
Mapping the protein phosphatase-2B anchoring site on AKAP79. Binding and inhibition of phosphatase activity are mediated by residues 315-360. J Biol Chem (2002) 1.86
The impact of computerized provider order entry on medication errors in a multispecialty group practice. J Am Med Inform Assoc (2010) 1.85
Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy. Sex Transm Dis (2006) 1.85
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (2010) 1.83
The where's and when's of kinase anchoring. Trends Biochem Sci (2006) 1.83
AKAP-Lbc nucleates a protein kinase D activation scaffold. Mol Cell (2004) 1.81
Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring. Proc Natl Acad Sci U S A (2003) 1.80
Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med (2003) 1.79
The WRP component of the WAVE-1 complex attenuates Rac-mediated signalling. Nat Cell Biol (2002) 1.77
Population-based metrics for the timing of HIV diagnosis, engagement in HIV care, and virologic suppression. AIDS (2012) 1.76
Migration distorts surveillance estimates of engagement in care: results of public health investigations of persons who appear to be out of HIV care. Sex Transm Dis (2014) 1.70
Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations? Int J Technol Assess Health Care (2010) 1.70
Networking with AKAPs: context-dependent regulation of anchored enzymes. Mol Interv (2010) 1.69
Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis (2012) 1.67
Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort study. Sex Transm Dis (2014) 1.66
Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett (2005) 1.66
HIV among African-born persons in the United States: a hidden epidemic? J Acquir Immune Defic Syndr (2008) 1.65
AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. Nat Cell Biol (2010) 1.64
The impact of e-prescribing on prescriber and staff time in ambulatory care clinics: a time motion study. J Am Med Inform Assoc (2007) 1.64
The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision. Ann Surg (2011) 1.63
Medicaid prior authorization and controlled-release oxycodone. Med Care (2008) 1.61
Determinants of recent HIV infection among Seattle-area men who have sex with men. Am J Public Health (2008) 1.61
Improving pediatric asthma outcomes in the community setting: does pharmaceutical care make a difference? J Am Pharm Assoc (Wash) (2002) 1.59
AKAP150 contributes to enhanced vascular tone by facilitating large-conductance Ca2+-activated K+ channel remodeling in hyperglycemia and diabetes mellitus. Circ Res (2013) 1.59
Trafficking of L-type calcium channels mediated by the postsynaptic scaffolding protein AKAP79. J Biol Chem (2002) 1.58
AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway. Mol Cell (2008) 1.57
Resource costs for asthma-related care among pediatric patients in managed care. Ann Allergy Asthma Immunol (2003) 1.57
Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. Clin Infect Dis (2005) 1.57
An evaluation of the reliability of HIV partner notification disposition coding by disease intervention specialists in the United States. Sex Transm Dis (2009) 1.57
HIV testing frequency among men who have sex with men attending sexually transmitted disease clinics: implications for HIV prevention and surveillance. J Acquir Immune Defic Syndr (2009) 1.55
Increased coupled gating of L-type Ca2+ channels during hypertension and Timothy syndrome. Circ Res (2010) 1.55
Spatial bridges for the importation of gonorrhea and chlamydial infection. Sex Transm Dis (2003) 1.54
Signaling complexes: junctions on the intracellular information super highway. Curr Biol (2002) 1.54
Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. Mol Cell (2011) 1.52
Enhanced molecular typing of treponema pallidum: geographical distribution of strain types and association with neurosyphilis. J Infect Dis (2010) 1.51
Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease. J Allergy Clin Immunol (2007) 1.50
Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor. J Biol Chem (2006) 1.48
Compartmentation of cyclic nucleotide signaling in the heart: the role of A-kinase anchoring proteins. Circ Res (2006) 1.48
PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. Biochem J (2004) 1.47
Full-length cardiac Na+/Ca2+ exchanger 1 protein is not phosphorylated by protein kinase A. Am J Physiol Cell Physiol (2011) 1.46
Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study. Pediatr Allergy Immunol (2006) 1.45
The timing of elective colectomy in diverticulitis: a decision analysis. J Am Coll Surg (2004) 1.45
Comparison of guideline-based control definitions and associations with outcomes in severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol (2008) 1.44